{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T21:53:38Z","timestamp":1770414818364,"version":"3.49.0"},"reference-count":29,"publisher":"American Society for Microbiology","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin. Vaccine Immunol."],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Subunit recombinant vaccines against classical swine fever virus (CSFV) are a promising alternative to overcome practical and biosafety issues with inactivated vaccines. One of the strategies in evaluation under field conditions is the use of a new marker E2-based vaccine produced in the milk of adenovirally transduced goats. Previously we had demonstrated the efficacy of this antigen, which conferred early protection and long-lasting immunity in swine against CSFV infection. Here, we have used a simpler downstream process to obtain and formulate the recombinant E2 glycoprotein expressed in the mammary gland. The expression levels reached approximately 1.7 mg\/ml, and instead of chromatographic separation of the antigen, we utilized a clarification process that eliminates the fat content, retains a minor amount of caseins, and includes an adenoviral inactivation step that improves the biosafety of the final formulation. In a vaccination and challenge experiment in swine, different doses of the E2 antigen contained within the clarified whey generated an effective immune response of neutralizing antibodies that protected all of the animals against a lethal challenge with CSFV. During the immunization and after challenge, the swine were monitored for adverse reactions related to the vaccine or symptoms of CSF, respectively. No adverse reactions or clinical signs of disease were observed in vaccinated animals, in which no replication of CSFV could be detected after challenge. Overall, we consider that the simplicity of the procedures proposed here is a further step toward the introduction and implementation of a commercial subunit vaccine against CSF.<\/jats:p>","DOI":"10.1128\/cvi.00416-14","type":"journal-article","created":{"date-parts":[[2014,10,2]],"date-time":"2014-10-02T08:23:52Z","timestamp":1412238232000},"page":"1628-1634","source":"Crossref","is-referenced-by-count":17,"title":["Effectiveness of the E2-Classical Swine Fever Virus Recombinant Vaccine Produced and Formulated within Whey from Genetically Transformed Goats"],"prefix":"10.1128","volume":"21","author":[{"given":"O.","family":"S\u00e1nchez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Barrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Farn\u00f3s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. C.","family":"Parra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. R.","family":"Salgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. A.","family":"Saavedra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. D.","family":"Meza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. I.","family":"Rivas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Cortez-San Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. R.","family":"Toledo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","published-online":{"date-parts":[[2014,10,1]]},"reference":[{"key":"key20180919073751_B1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0034-5288(03)00076-6","article-title":"Classical swine fever\u2014an update","volume":"75","author":"Paton","year":"2003","journal-title":"Res. Vet. Sci."},{"key":"key20180919073751_B2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S1090-0233(02)00112-0","article-title":"Clinical signs and epidemiology of classical swine fever: a review of new knowledge","volume":"165","author":"Moennig","year":"2003","journal-title":"Vet. J."},{"key":"key20180919073751_B3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.meegid.2014.04.008","article-title":"Vaccination influences the evolution of classical swine fever virus","volume":"25","author":"Ji","year":"2014","journal-title":"Infect. Genet. Evol."},{"key":"key20180919073751_B4","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1016\/j.vaccine.2014.02.006","article-title":"First assessment of classical swine fever marker vaccine candidate CP7_E2alf for oral immunization of wild boar under field conditions","volume":"32","author":"Feliziani","year":"2014","journal-title":"Vaccine"},{"key":"key20180919073751_B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virusres.2013.10.025","article-title":"The challenges of classical swine fever control: modified live and E2 subunit vaccines","volume":"179","author":"Huang","year":"2014","journal-title":"Virus Res."},{"key":"key20180919073751_B6","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1128\/JVI.65.9.4705-4712.1991","article-title":"Hog cholera virus: molecular composition of virions from a pestivirus","volume":"65","author":"Thiel","year":"1991","journal-title":"J. Virol."},{"key":"key20180919073751_B7","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1099\/0022-1317-80-5-1157","article-title":"Localization of pestiviral envelope proteins E(rns) and E2 at the cell surface and on isolated particles","volume":"80","author":"Weiland","year":"1999","journal-title":"J. Gen. Virol."},{"key":"key20180919073751_B8","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.1128\/JVI.67.9.5435-5442.1993","article-title":"Glycoprotein E1 of hog cholera virus expressed in insect cells protects swine from hog cholera","volume":"67","author":"Hulst","year":"1993","journal-title":"J. Virol."},{"key":"key20180919073751_B9","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.20506\/rst.25.3.1715","article-title":"Assessment of classical swine fever diagnostics and vaccine performance","volume":"25","author":"Blome","year":"2006","journal-title":"Rev. Sci. Tech."},{"key":"key20180919073751_B10","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1099\/0022-1317-77-11-2737","article-title":"Classical swine fewer virus (CSFV) envelope glycoprotein E2 containing one structural antigenic unit protects pigs from lethal CSFV challenge","volume":"77","author":"van Rijn","year":"1996","journal-title":"J. Gen. Virol."},{"key":"key20180919073751_B11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0378-1135(00)00146-2","article-title":"Development of a classical swine fever subunit marker vaccine and companion diagnostic test","volume":"73","author":"Moormann","year":"2000","journal-title":"Vet. Microbiol."},{"key":"key20180919073751_B12","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.vaccine.2007.11.014","article-title":"Classical swine fever virus E2 glycoprotein antigen produced in adenovirally transduced PK-15 cells confers complete protection in pigs upon viral challenge","volume":"26","author":"S\u00e1nchez","year":"2008","journal-title":"Vaccine"},{"key":"key20180919073751_B13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.vetimm.2008.10.330","article-title":"Thermal stress treatment does not affect the stability and protective capacity of goat milk derived E2-marker vaccine formulation against CSFV","volume":"127","author":"Barrera","year":"2009","journal-title":"Vet. Immunol. Immunopathol."},{"key":"key20180919073751_B14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.vetimm.2009.06.015","article-title":"Early onset and long lasting protection in pigs provided by a classical swine fever E2-vaccine candidate produced in the milk of goats","volume":"133","author":"Barrera","year":"2010","journal-title":"Vet. Immunol. Immunopathol."},{"key":"key20180919073751_B15","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jbiotec.2007.09.014","article-title":"Highly protective E2-CSFV vaccine candidate produced in the mammary gland of adenoviral transduced goats","volume":"133","author":"Toledo","year":"2008","journal-title":"J. Biotechnol."},{"key":"key20180919073751_B16","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jbiosc.2011.07.018","article-title":"Production of first generation adenoviral vectors for preclinical protocols: amplification, purification and functional titration","volume":"112","author":"Armend\u00e1riz-Borunda","year":"2011","journal-title":"J. Biosci. Bioeng."},{"key":"key20180919073751_B17","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.abb.2010.05.006","article-title":"The N-glycosylation of classical swine fever virus E2 glycoprotein extracellular domain expressed in the milk of goat","volume":"500","author":"Montesino","year":"2010","journal-title":"Arch. Biochem. Biophys."},{"key":"key20180919073751_B18","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1128\/CMR.00005-07","article-title":"Current status of veterinary vaccines","volume":"20","author":"Meeusen","year":"2007","journal-title":"Clin. Microbiol. Rev."},{"key":"key20180919073751_B19","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0264-410X(00)00189-4","article-title":"An experimental infection with classical swine fever in E2 sub-unit marker-vaccine vaccinated and in non-vaccinated pigs","volume":"19","author":"Dewulf","year":"2000","journal-title":"Vaccine"},{"key":"key20180919073751_B20","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0378-1135(00)00306-0","article-title":"Duration of the protection of an E2 subunit marker vaccine against classical swine fever after a single vaccination","volume":"78","author":"de Smit","year":"2001","journal-title":"Vet. Microbiol."},{"key":"key20180919073751_B21","doi-asserted-by":"publisher","first-page":"5665","DOI":"10.1016\/j.vaccine.2006.12.036","article-title":"Novel marker vaccines against classical swine fever","volume":"25","author":"Beer","year":"2007","journal-title":"Vaccine"},{"key":"key20180919073751_B22","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1023\/A:1008934912555","article-title":"Transgenic animal bioreactors","volume":"9","author":"Houdebine","year":"2000","journal-title":"Transgenic Res."},{"key":"key20180919073751_B23","unstructured":"ToledoJRS\u00e1nchezOBarreraMFigueroaNPrietoYRodr\u00edguezMPFriasMTBorrotoC. April 2013. US patent 8,409,562 B2."},{"key":"key20180919073751_B24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/0378-1135(88)90036-3","article-title":"The protective value of vaccine-induced neutralizing antibody titres in swine fever","volume":"16","author":"Terpstra","year":"1988","journal-title":"Vet. Microbiol."},{"key":"key20180919073751_B25","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1749-6632.1960.tb40931.x","article-title":"Investigations of the use of beta-propiolactone in virus inactivation","volume":"83","author":"Logrippo","year":"1960","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"key20180919073751_B26","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/biot.201100455","article-title":"Biosafety evaluation of recombinant protein production in goat mammary gland using adenoviral vectors: preliminary study","volume":"8","author":"Rodr\u00edguez","year":"2012","journal-title":"Biotechnol. J."},{"key":"key20180919073751_B27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.vetimm.2013.10.014","article-title":"A promising multiple-epitope recombinant vaccine against classical swine fever virus","volume":"157","author":"Tian","year":"2014","journal-title":"Vet. Immunol. Immunopathol."},{"key":"key20180919073751_B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jbiotec.2014.01.007","article-title":"Enhancing expression of the classical swine fever virus glycoprotein E2 in yeast and its application to a blocking ELISA","volume":"174","author":"Cheng","year":"2014","journal-title":"J. Biotechnol."},{"key":"key20180919073751_B29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.vetmic.2013.12.002","article-title":"Efficacy of marker vaccine candidate CP7_E2alf against challenge with classical swine fever virus isolates of different genotypes","volume":"169","author":"Blome","year":"2014","journal-title":"Vet. Microbiol."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1128\/CVI.00416-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:50:10Z","timestamp":1627591810000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00416-14"}},"subtitle":[],"editor":[{"given":"M. F.","family":"Pasetti","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,10,1]]},"references-count":29,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2014,11,25]]},"published-print":{"date-parts":[[2014,12]]}},"alternative-id":["10.1128\/CVI.00416-14"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00416-14","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,1]]}}}